Severe Acute Respiratory Syndrome Coronavirus 2 Infection Clinical Trial
Official title:
A Phase 3 Open-Label, Single-Arm Study to Evaluate the Safety and Immunogenicity of a JN.1 Subvariant SARS CoV-2 rS Vaccine
Phase 3 study assessing the safety and effectiveness of a single dose of a SARS-CoV-2 nanoparticle vaccine (NVX CoV2705) adjuvanted with Matrix-M™ in previously vaccinated adults. About 100 participants will receive the vaccine and be monitored for safety and immune response for up to 35 days post-vaccination.
This is a Phase 3, open-label, single arm study to evaluate the safety and immunogenicity of a single dose of a JN.1 subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine (SARS-CoV-2 rS) adjuvanted with Matrix-M™ (NVX CoV2705) in previously vaccinated adults. Approximately 100 participants will be enrolled to receive a single dose of NVX CoV2705 on Day 0 and remain on study for immunogenicity and safety data collection up to 35 days post-vaccination. ;